Advertisement

Document › Details
Eckert & Ziegler SE. (1/14/25). "Press Release: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture". Berlin.
![]() |
Region | China |
![]() |
Organisation | Qi Kang Medical Technology (Changzhou) Co., Ltd. |
Group | Eckert & Ziegler (Group) | |
Organisation 2 | DC Pharma (CN) | |
![]() |
Product | Actinium-225 alpha-emitting radioisotope (Ac-225) |
Product 2 | RADIOPHARMACEUTICAL (RPT) | |
![]() |
Person | Riehle, Karolin (Eckert & Ziegler 202212 Investor Relations + PR) |
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales.
For Eckert & Ziegler the licence and collaboration agreement is an important step towards establishing the company as a major supplier of Ac-225 for the radiopharmaceutical industry. Eckert & Ziegler is already supplying Ac-225 and will be able to provide the market with significantly increased quantities of Ac-225 in GMP quality from 2025.
Currently, Ac-225-based radiopharmaceuticals are under clinical investigation for various cancers, including prostate tumors, colorectal cancer, and leukemia. A substantial increase in the demand for Ac-225 is projected over the next decade, driven by its expanding clinical applications and the promising results seen in ongoing trials. Despite its therapeutic promise, sufficient quantities of Ac-225 remain scarce.
Contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
Record changed: 2025-01-21 |
Advertisement

More documents for Eckert & Ziegler (Group)
- [1] Eckert & Ziegler SE. (1/13/25). "Press Release: Eckert & Ziegler and GlyTherix Extend Collaboration with Actinium-225 Supply Agreement". Berlin & Sydney....
- [2] Eckert & Ziegler SE. (12/13/24). "Press Release: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW". Berlin....
- [3] Eckert & Ziegler SE. (12/5/24). "Press Release: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments". Berlin....
- [4] Eckert & Ziegler SE. (12/3/24). "Press Release: Eckert & Ziegler – Changes in the Executive Board and Supervisory Board". Berlin....
- [5] Eckert & Ziegler AG. (1/8/24). "Press Release: Eckert & Ziegler and ArtBio Announce Manufacturing and Supply Partnership for Lead-212 Conjugates". Berlin & Cambridge, MA....
- [6] Eckert & Ziegler AG. (11/14/23). "Press Release: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes". Berlin....
- [7] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
- [8] Eckert & Ziegler AG. (5/15/23). "Press Release: Reorganization in the Executive Board of Eckert & Ziegler". Berlin....
- [9] Eckert & Ziegler AG. (4/4/23). "Press Release: Eckert & Ziegler to Supply Point Biopharma with Actinium-225". Berlin & Indianapolis, IN....
- [10] Eckert & Ziegler Strahlen- und Medizintechnik AG. (12/19/22). "Press Release: Changes in the Management Board of Eckert & Ziegler. Insider Information Pursuant to Article 17 MAR". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top